TY - JOUR
T1 - Real world trials to answer real world questions
AU - Freemantle, Nick
AU - Blonde, L
AU - Bolinder, B
AU - Gerber, RA
AU - Hobbs, Frederick
AU - Martinez, L
AU - Ross, S
PY - 2005/1/1
Y1 - 2005/1/1
N2 - Currently, there is a discrepancy between clinical trials designed to assess the efficacy and safety of a new medication under investigation and the real-life questions that need to be addressed regarding the clinical use of the medication by patients, healthcare professionals and society. The data necessary to obtain regulatory approval may be of limited relevance to policy makers when calculating economic parameters such as value for money or cost effectiveness. 'Real-world' studies examine questions relevant to health policy and reimbursement. There are many different forms of clinical trials, but in designing trials incorporating realistic budget impact estimates the important issue is to ensure we are asking a sensible question and attempting to answer it with an appropriate experimental design. As an example, a real-world trial currently underway that examines scenarios of introducing inhaled insulin into clinical practice is described.
AB - Currently, there is a discrepancy between clinical trials designed to assess the efficacy and safety of a new medication under investigation and the real-life questions that need to be addressed regarding the clinical use of the medication by patients, healthcare professionals and society. The data necessary to obtain regulatory approval may be of limited relevance to policy makers when calculating economic parameters such as value for money or cost effectiveness. 'Real-world' studies examine questions relevant to health policy and reimbursement. There are many different forms of clinical trials, but in designing trials incorporating realistic budget impact estimates the important issue is to ensure we are asking a sensible question and attempting to answer it with an appropriate experimental design. As an example, a real-world trial currently underway that examines scenarios of introducing inhaled insulin into clinical practice is described.
UR - http://www.scopus.com/inward/record.url?scp=26444508546&partnerID=8YFLogxK
U2 - 10.2165/00019053-200523080-00001
DO - 10.2165/00019053-200523080-00001
M3 - Article
C2 - 16097837
VL - 23
SP - 747
EP - 754
JO - PharmacoEconomics
JF - PharmacoEconomics
ER -